Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning potential violations of the federal securities laws.
ADMA Biologics announced a delay in filing its Form 10-K, citing an ongoing audit by KPMG focused on evaluating internal controls. Following this news, shares of ADMA Biologics fell over 8% in intraday trading on March 4, 2025.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





